Phosphodiesterase 10 A Regulates Alcohol and Saccharin Self-Administration in Rats

Accumulating evidence suggests that selective M4 muscarinic acetylcholine receptor (mAChR) activators may offer a novel strategy for the treatment of psychosis. However, previous efforts to develop selective M4 activators were unsuccessful because of the lack of M4 mAChR subtype specificity and off-target muscarinic adverse effects. We recently developed VU0152100, a highly selective M4 positive allosteric modulator (PAM) that exerts central effects after systemic administration. We now report that VU0152100 dose-dependently reverses amphetamine-induced hyperlocomotion in rats and wild-type mice, but not in M4 KO mice. VU0152100 also blocks amphetamine-induced disruption of the acquisition of contextual fear conditioning and prepulse inhibition of the acoustic startle reflex. These effects were observed at doses that do not produce catalepsy or peripheral adverse effects associated with non-selective mAChR agonists. To further understand the effects of selective potentiation of M4 on region-specific brain activation, VU0152100 alone and in combination with amphetamine were evaluated using pharmacologic magnetic resonance imaging (phMRI). Key neural substrates of M4-mediated modulation of the amphetamine response included the nucleus accumbens (NAS), caudate-putamen (CP), hippocampus, and medial thalamus. Functional connectivity analysis of phMRI data, specifically assessing correlations in activation between regions, revealed several brain networks involved in the M4 modulation of amphetamine-induced brain activation, including the NAS and retrosplenial cortex with motor cortex, hippocampus, and medial thalamus. Using in vivo microdialysis, we found that VU0152100 reversed amphetamine-induced increases in extracellular dopamine levels in NAS and CP. The present data are consistent with an antipsychotic drug-like profile of activity for VU0152100. Taken together, these data support the development of selective M4 PAMs as a new approach to the treatment of psychosis and cognitive impairments associated with psychiatric disorders such as schizophrenia.

[1]  M. Roger,et al.  Topographical organization of the projections from physiologically identified areas of the motor cortex to the striatum in the rat , 1992, Neuroscience Research.

[2]  J. Wess,et al.  A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors , 2010, The Journal of Neuroscience.

[3]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[4]  C. McKittrick,et al.  Catecholamine mapping within nucleus accumbens: differences in basal and amphetamine‐stimulated efflux of norepinephrine and dopamine in shell and core , 2007, Journal of neurochemistry.

[5]  J. Wess,et al.  Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. , 2011, European journal of pharmacology.

[6]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[7]  S. Ogawa,et al.  Biophysical and Physiological Origins of Blood Oxygenation Level-Dependent fMRI Signals , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  B R Rosen,et al.  Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.

[9]  K. Perry,et al.  The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex , 2001, Biological Psychiatry.

[10]  S. Jadhav,et al.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. , 2010, ACS chemical neuroscience.

[11]  S. Parasuraman,et al.  Protein data bank , 2012, Journal of pharmacology & pharmacotherapeutics.

[12]  J. Lieberman,et al.  What CATIE found: results from the schizophrenia trial. , 2008, Psychiatric services.

[13]  T. Bonner,et al.  Identification of a family of muscarinic acetylcholine receptor genes. , 1987, Science.

[14]  S. Jadhav,et al.  Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  D. Lovinger,et al.  Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. , 2012, Cell reports.

[16]  M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition , 2012, Molecular Brain.

[17]  J M Wyss,et al.  Connections of the retrosplenial dysgranular cortex in the rat , 1992, The Journal of comparative neurology.

[18]  T. Bonner,et al.  Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes , 1988, Neuron.

[19]  P. Sexton,et al.  Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.

[20]  L. Dawson,et al.  Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. , 2009, European journal of pharmacology.

[21]  B. Rosen,et al.  Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation , 1998, Magnetic resonance in medicine.

[22]  J. Wess,et al.  Involvement of a Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4 Preferring Muscarinic Receptor Agonist Xanomeline , 2011, The Journal of Neuroscience.

[23]  D. McKinzie,et al.  Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  J. Wess,et al.  M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Angelo Bifone,et al.  Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. , 2007, Magnetic resonance imaging.

[26]  J. Wess,et al.  Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice , 2011, Psychopharmacology.

[27]  S. Sesack,et al.  Projections from the rat pedunculopontine and laterodorsal tegmental nuclei to the anterior thalamus and ventral tegmental area arise from largely separate populations of neurons , 2011, Brain Structure and Function.

[28]  D. Allison,et al.  Weight effects associated with antipsychotics: A comprehensive database analysis , 2009, Schizophrenia Research.

[29]  M. Quirk,et al.  A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.

[30]  Sharon L Ripp,et al.  Evaluation of models for predicting drug–drug interactions due to induction , 2010, Expert opinion on drug metabolism & toxicology.

[31]  S. Irwin,et al.  Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.

[32]  J S Ward,et al.  Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines . , 1992, Journal of medicinal chemistry.

[33]  T. Werge,et al.  The Muscarinic M1/M4 Receptor Agonist Xanomeline Exhibits Antipsychotic-Like Activity in Cebus apella Monkeys , 2003, Neuropsychopharmacology.

[34]  A. Deutch,et al.  Differential Activation of Orexin Neurons by Antipsychotic Drugs Associated with Weight Gain , 2002, The Journal of Neuroscience.

[35]  Angelo Bifone,et al.  Selective dopamine D3 receptor antagonist SB‐277011‐A potentiates phMRI response to acute amphetamine challenge in the rat brain , 2004, Synapse.

[36]  P. Enrico,et al.  The effects of cortical ablation on d-amphetamine-induced changes in striatal dopamine turnover and ascorbic acid catabolism in the rat , 1992, Neuroscience Letters.

[37]  S. Parasuraman,et al.  Measurement of invasive blood pressure in rats , 2012, Journal of pharmacology & pharmacotherapeutics.

[38]  J. Lieberman,et al.  Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. , 2003, The American journal of psychiatry.

[39]  D. Wong,et al.  Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  Carrie K. Jones,et al.  Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia , 2012, Neuropsychopharmacology.

[41]  T. van Groen,et al.  Connections of the retrosplenial granular b cortex in the rat , 1990, The Journal of comparative neurology.

[42]  D. Airey,et al.  5-HT2C receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice , 2006, Neuroscience Research.

[43]  F. Bymaster,et al.  Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice , 2000, Schizophrenia Research.

[44]  J. Wess,et al.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Kari A. Johnson,et al.  An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. , 2008, Nature chemical biology.

[46]  Michael Gill,et al.  Attention Deficit/Hyperactivity Disorder-Derived Coding Variation in the Dopamine Transporter Disrupts Microdomain Targeting and Trafficking Regulation , 2012, The Journal of Neuroscience.

[47]  M. Foster Olive,et al.  Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models , 2012, The Journal of Neuroscience.

[48]  Craig Mallinckrodt,et al.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. , 2008, The American journal of psychiatry.

[49]  A. Christopoulos,et al.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.

[50]  A. Blokland,et al.  Effects of the cognition impairer MK-801 on learning and memory in mice and rats , 2011, Behavioural Brain Research.

[51]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[52]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[53]  S. Cragg,et al.  Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum , 2010, The Journal of Neuroscience.

[54]  J D Watson,et al.  Nonparametric Analysis of Statistic Images from Functional Mapping Experiments , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  J. Wess,et al.  An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine , 2012, Psychopharmacology.

[56]  Craig W. Lindsley,et al.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.

[57]  R. Blakely,et al.  Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala , 2005, Neuropharmacology.

[58]  A. Gozzi,et al.  A robust experimental protocol for pharmacological fMRI in rats and mice , 2012, Journal of Neuroscience Methods.

[59]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[60]  S. Lightowler,et al.  The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. , 2001, The Journal of pharmacology and experimental therapeutics.

[61]  A. Deutch,et al.  Dopaminergic regulation of orexin neurons , 2005, The European journal of neuroscience.

[62]  P Jeffrey Conn,et al.  Attenuation of Cocaine's Reinforcing and Discriminative Stimulus Effects via Muscarinic M1 Acetylcholine Receptor Stimulation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[63]  Angelo Bifone,et al.  In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI , 2007, NeuroImage.

[64]  Joseph E LeDoux,et al.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. , 1992, Behavioral neuroscience.

[65]  J. Gore,et al.  Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation , 2010, Neuroscience.

[66]  N. Byun,et al.  Muscarinic receptor pharmacology and circuitry for the modulation of cognition. , 2012, Handbook of experimental pharmacology.

[67]  R. Roth,et al.  Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: An anterograde tract‐tracing study with Phaseolus vulgaris leucoagglutinin , 1989, The Journal of comparative neurology.

[68]  A. Deutch,et al.  Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.

[69]  Christian C. Felder,et al.  Muscarinic Acetylcholine Receptor Knockout Mice , 2004 .

[70]  J. Yeomans.  Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions. , 2012, Handbook of experimental pharmacology.